Professional Documents
Culture Documents
Susan M. Domchek, MD
Basser Professor of Oncology
University of Pennsylvania
Risk Factors for Breast Cancer
Sex
Age
Family history
Depends on specific of family history
Depends on whether there is a known genetic susceptibility
Reproductive history
Early first period
Late last period
Postmenopausal estrogen use
Late first child
No breast feeding
ETOH
Obesity
Lack of exercise
Germline vs Somatic Genetics
Single
Common nucleotide
Variants
polymorphisms
Allele Frequency
1 2 5 10
Relative Risk
Hereditary breast cancer
Predicted
SNP , 14%
Known
SNPs, 14%
Unknown,
50%
Moderate
penetrance ,
4%
Other high
penetrance,
3% BRCA1/2,
15%
Risk Assessment
Disease Prevention
Therapeutics
all mutations
90% linkage families
80% Penn Clinic
Brose et al JNCI 2002
70%
Streuwing, 1997
60%
185delAG, 5382insC
50%
Hopper, 1999
40% consecutive breast ca
cases
30% Fodor, 1998
185delAG,
20% 5382insC
10% consecutive breast
ca cases
0%
30 40 50 60 70 80 85
AgeAge
Genetic modifiers: CIMBA
1.0
5%, 95%
10%, 90% Polygenic risk
Average
scores (PRS) using
BRCA1 carriers
BC susceptibility
0.8
SNPs identified
through
population-based
Breast cancer risk
0.6
GWAS
15,252 BRCA1
0.4
8,211 BRCA2
0.2
0.0
30 40 50 60 70 80
Age
Kuchenbaecker et al in press 2016
Risk Reducing Salpingo-Oophorectomy and the
risk of breast cancer
No Prior Breast Cancer
Total BRCA1 BRCA2
Total Participants 1,370 869 501
HR (95% CI) 0.54 (0.37-0.79) 0.63 (0.41-0.96) 0.36 (0.16-0.82)
Platinum sensitive
(N = 39) 18 46 (3063) 8.2 (5.613.5)
Platinum resistant
(N = 81) 24 30 (2041) 8.0 (4.814.8)
Platinum refractory
(N = 14) 2 14 (243) 6.4 (5.47.4)
Platinum status
unknown (N = 3) 2 67 (999) 6.3 (4.77.9)
Ongoing studies
In the US - this has become very complicated.
Ambry Ambry Ambry
Myriad Uwash Fulgent Myriad Uwash Fulgent Fulgent
Gene Cancer Invitae GeneDx Gene Cancer Invitae GeneDx Gene Renal or
MyRisk BROCA * MyRisk BROCA * *
Next Next PGL
# of genes 25 28 28 30 50 110 BARD1 x x x x x FH x x
APC x x x x x x RAD51D x x x x x FLCN x x
ATM x x x x x x MRE11A x x x MAX x x
BMPR1A x x x x x x RAD50 x x x MET x x
BRCA1 x x x x x x NF1 x x MITF x x
BRCA2 x x x x x x VHL Renal/PGL x x x x SDHA x x
BRIP1 x x x x x x MEN1 x x x SDHAF2 x x
CDH1 x x x x x x RET PGL x x x TMEM127 x x
CDK4 x x x x x x PTCH1 x x TSC1 x x
CDKN2A x x x x x x PALLD x TSC2 x x
CHEK2 x x x x x x XRCC2 x x x
EPCAM x x x x x x CHEK1 x x *Rest of genes on Fulgent:
MLH1 x x x x x x AXIN2 x x BLM, BUB1B, CTNNB1,
MSH2 x x x x x x FANCC x x CYLD, DDB2, DICER1, EGFR,
ATR x x EGLN1, ERCC2, ERCC3,
MSH6 x x x x x x
ERCC4, ERCC5, EXO1, EXT1,
MUTYH x x x x x x BAP1 x x
EXT2, FANCA, FANCB,
NBN x x x x x x GALNT12 x x FANCD2, FANCE, FANCF,
PALB2 x x x x x x HOXB13 x x FANCG, FANCI, FANCL,
PMS2 x x x x x x POLD1 x x FANCM, GPC3, HRAS,
PTEN x x x x x x PRSS1 x x KIF1B, KIT, MC1R, MPL,
RAD51A x x MSH3, NF2, PDGFRA,
RAD51C x x x x x x
SDHB x x PICALM, PMS1, PRKAR1A,
SMAD4 x x x x x x Renal/PGL
PRKDC, PTPN11, RB1,
STK11 x x x x x x SDHC Renal/PGL x x
RBBP8, RBM15, RECQL4,
TP53 x x x x x x SDHD Renal/PGL x x ROBO2, SBDS, SLX4,
AKT1 x SMARCB1, SUFU, TERT,
CTNNA1 x TSHR, TYR, WRN ,WT1,
FAM175A x XPA, XPC, XRCC3
GEN1 x
GREM1 x
PIK3CA x
POLE x
PPM1D x
TP53BP1 x
Revolution of genetic testing
Assess
patient
Disclose
result and
reassess
New approach?
Assess
patient
Send
multigene
panel
Disclose
result and
reassess
Why do this?
Risk assessment
Value of the true negative
Risk of breast and as well as risk of second primary
cancer
Risk of other cancers (Ovarian cancer risk for
BRCA1/2 was a major reason for rapid uptake of
testing)
Clinical utility
Therapeutics
Prognosis: may impact administration of adjuvant
therapy
Drug development/selection
Genetic testing can be very useful to patients and their family members
Both the prevent and to treat cancer
Genetic testing is continuously evolving
BRCA1 and BRCA2 mutations are the most commonly found and we
have reasonable data on how to manage
New genetics tests are often less clear in terms of how to change
patients care and improve patient outcome